首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2019年 10期HBV感染“新型”生物标志物的临床应用 => 肝脏肿瘤 =>增强CT和增强MRI..
增强CT和增强MRI对肝细胞癌经肝动脉化疗栓塞术后病灶存活或复发诊断价值的Meta分析
Value of contrast-enhanced computed tomography and magnetic resonance imaging in diagnosis of residual or recurrent lesion after transcatheter arterial chemoembolization in hepatocellular carcinoma: A Meta-analysis
文章发布日期:2019年09月05日  来源:  作者:李 栋,罗天杨,冉亚伟  点击次数:201次  下载次数:16次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】: 目的 系统评价增强CT(CECT)和增强磁共振成像(CEMRI)诊断肝细胞癌(HCC)经肝动脉化疗栓塞术(TACE)术后存活或复发病灶的临床价值。方法 检索PubMed、Embase、Cochrane Library、Web of Science、CNKI、万方数据库中CECT和(或)CEMRI诊断TACE术后存活或复发HCC病灶的研究,检索时间截止至2019年4月。由2位研究人员独立筛选文献、提取资料后,根据QUADAS-2标准评价纳入研究的偏倚风险后,采用Stata 12.0和Revman 5.3软件汇总分析敏感度、特异度、受试者工作特征曲线下面积(AUC)。结果 共纳入13篇CECT及13篇CEMRI诊断TACE术后存活或复发HCC病灶的研究,分别包括748例患者的934个病灶和557例患者的847个病灶。CECT诊断TACE术后存活或复发HCC病灶的13项研究中存在高度异质性(P=0.001,Q=12.56,I2=84.08%);CEMRI诊断TACE术后存活或复发HCC病灶的13项研究中不存在明显异质性(P=0.473,Q=0.11,I2=0)。CECT诊断TACE术后存活或复发HCC病灶的敏感度、特异度和AUC分别为72%[95%可信区间(95%CI):66%~78%]、 99%(95%CI:93%~100%)和0.87(95%CI:0.83~0.89);CEMRI的敏感度、特异度和AUC分别为88%(95%CI:82%~93%)、96 %(95%CI:91%~98%)和0.98(95%CI:0.96~0.99)。CECT诊断TACE术后存活或复发病灶的敏感度明显低于CEMRI (Z=2.12,P=0.03)。结论 相比于CECT,CEMRI对TACE术后存活或复发病灶具有极高的诊断效能,是诊断TACE术后存活或复发病灶的有效方法。
【Abstract】: Objective To systematically evaluate the value of contrast-enhanced computed tomography (CECT) and contrast-enhanced magnetic resonance imaging (CEMRI) in the diagnosis of residual or recurrent lesion after transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC). Methods PubMed, Embase, Cochrane Library, Web of Science, CNKI, and Wanfang Data were searched for studies on CECT and/or CEMRI in the diagnosis of residual or recurrent lesion after TACE published up to April 2019. After two reviewers independently performed literature screening, data extraction, and assessment of the risk of bias using the QUADAS-2 tool, Stata 12.0 and RevMan 5.3 were used to analyze pooled sensitivity, specificity, and area under the receiver operator characteristic curve (AUC). Results A total of 13 studies on CECT and 13 studies on CEMRI in the diagnosis of residual or recurrent HCC lesion after TACE were included, with 934 lesions from 748 patients and 847 lesions from 557 patients, respectively. High heterogeneity was observed in the 13 studies on CECT in the diagnosis of residual or recurrent HCC lesion after TACE (P=0.001, Q=12.56, I2=84.08%), while no significant heterogeneity was observed in the 13 studies on CEMRI (P=0.473, Q=0.11, I2=0). In the diagnosis of residual or recurrent HCC lesion after TACE, CECT had a sensitivity of 72% (95% confidence interval [CI]: 66%-78%), a specificity of 99% (95% CI: 93%-100%), and an AUC of 0.87 (95% CI: 0.83-0.89), and CEMRI had a sensitivity of 88% (95% CI: 82%-93%), a specificity of 96% (95% CI: 91%-98%), and an AUC of 0.98 (95% CI: 0.96-0.99). CECT had a significantly lower sensitivity than CEMRI in the diagnosis of residual or recurrent HCC lesion after TACE (Z=2.12, P=0.03). Conclusion In comparison with CECT, CEMRI has an extremely higher diagnostic efficiency in the diagnosis of residual or recurrent HCC lesion after TACE and is thus an effective method for diagnosis.
【关键字】:癌, 肝细胞; 体层摄影术,X线计算机; 磁共振成像; Meta分析(主题)
【Key words】:carcinoma, hepatocellular; tomography, X-Ray computed; magnetic resonance imaging; Meta-analysis as topic
【引证本文】:LI D, LUO TY, RAN YW. Value of contrast-enhanced computed tomography and magnetic resonance imaging in diagnosis of residual or recurrent lesion after transcatheter arterial chemoembolization in hepatocellular carcinoma: A Meta-analysis[J]. J Clin Hepatol, 2019, 35(10): 2214-2219. (in Chinese)
李栋, 罗天杨, 冉亚伟. 增强CT和增强MRI诊断肝细胞癌经肝动脉化疗栓塞术后病灶存活或复发价值的Meta分析[J]. 临床肝胆病杂志, 2019, 35(10): 2214-2219.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号